Hoffmann-la Roche Inc.

Gottfried Alber

Peter Angehrn

Jane Andre Rogerson

Michael John Mulqueen

Frank Albert Mattner

Kathrin Palmer

Jacqueline Anne Carr

The present invention provides a combination of IL-12 and IFN.alpha. together with a pharmaceutically acceptable carrier useful for treatment and prophylaxis of infectious diseases, preferably chronic infectious diseases and more preferably viral infections, e.g. HSV, HIV, Hepatitis B, Hepatitis C, papilloma etc., bacterial infections, e.g. tuberculosis, salmonellosis, listeriosis, etc., and parasite infections, e.g. malaria, leishmaniasis, and schistosomiasis. These compositions are characterized by the synergistic interaction of IL-12 and IFN.alpha.. The present invention also provides the use of the above combination for the treatment and prophylaxis of infectious diseases.

Use of IL-12 and IFN.alpha. for the treatment of infectious diseases

The present invention is directed to products containing G-CSF and a TNF binding protein and compositions of G-CSF and TNF-BP, and methods of treating and/or preventing septic shock by administering the products and compositions of the invention.

Compositions of G-CSF and TNF-BP for prophylaxis and treatment of septic

Growing community of inventors

Grenzach-Whylen, Germany

Gottfried Alber